Results
| . | IdCSA . | IdCSA + IdMTX . | P . |
|---|---|---|---|
| PMN > 0.5 × 109/L | 12 (11-20) | 16 (12-21) | <.0001* |
| aGvHD | |||
| Grade 0-I | 11 | 21 | |
| Grade II-III | 17 | 11 | .037† |
| Median day (range) | 14 (7-40) | 17 (7-57) | .1* |
| cGvHD | |||
| Absent | 3 | 7 | |
| Limited | 12 | 12 | |
| Extensive | 11 | 9 | .2† |
| Causes of death | |||
| Relapse | 6 | 3 | |
| GvHD | 1 | 1 | |
| Infections (+IP) | 2 | 2 | |
| Heart failure | 0 | 1 | |
| Multiorgan failure | 0 | 1 | |
| Survival | |||
| Alive (%) | 19 (68) | 24 (74) | |
| Median day (range) | 2,119 (904-2,539) | 1,728 (910-2,476) | .16* |
| Relapse | |||
| Relapsed (%) | 8 (29) | 4 (13) | |
| Median day (range) | 266 (64-1,175) | 115 (80-954) | .6* |
| TRM | 11% | 17% | .6‡ |
| . | IdCSA . | IdCSA + IdMTX . | P . |
|---|---|---|---|
| PMN > 0.5 × 109/L | 12 (11-20) | 16 (12-21) | <.0001* |
| aGvHD | |||
| Grade 0-I | 11 | 21 | |
| Grade II-III | 17 | 11 | .037† |
| Median day (range) | 14 (7-40) | 17 (7-57) | .1* |
| cGvHD | |||
| Absent | 3 | 7 | |
| Limited | 12 | 12 | |
| Extensive | 11 | 9 | .2† |
| Causes of death | |||
| Relapse | 6 | 3 | |
| GvHD | 1 | 1 | |
| Infections (+IP) | 2 | 2 | |
| Heart failure | 0 | 1 | |
| Multiorgan failure | 0 | 1 | |
| Survival | |||
| Alive (%) | 19 (68) | 24 (74) | |
| Median day (range) | 2,119 (904-2,539) | 1,728 (910-2,476) | .16* |
| Relapse | |||
| Relapsed (%) | 8 (29) | 4 (13) | |
| Median day (range) | 266 (64-1,175) | 115 (80-954) | .6* |
| TRM | 11% | 17% | .6‡ |